Shares of Auris Medical Holding AG (NASDAQ:EARS) rose 3.2% during mid-day trading on Monday . The stock traded as high as $4.26 and last traded at $4.14, with a volume of 90,302 shares trading hands. The stock had previously closed at $4.01.

EARS has been the subject of several research reports. Leerink Swann reaffirmed a “buy” rating on shares of Auris Medical Holding AG in a research note on Thursday, May 12th. Jefferies Group reaffirmed a “buy” rating on shares of Auris Medical Holding AG in a research note on Friday, June 10th. Finally, Zacks Investment Research upgraded shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Tuesday, July 12th.

The firm’s 50-day moving average is $3.92 and its 200-day moving average is $3.98. The stock’s market cap is $142.12 million.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. During the same quarter in the previous year, the business posted ($0.28) EPS. Equities research analysts predict that Auris Medical Holding AG will post ($1.01) earnings per share for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.